Charles Schwab Investment Management Inc. Buys 45,090 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Charles Schwab Investment Management Inc. increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,812,502 shares of the company's stock after purchasing an additional 45,090 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.39% of Roivant Sciences worth $33,272,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ROIV. TOMS Capital Investment Management LP purchased a new stake in shares of Roivant Sciences in the 3rd quarter valued at $46,333,000. FMR LLC raised its holdings in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after buying an additional 2,593,910 shares during the last quarter. Geode Capital Management LLC raised its holdings in Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after buying an additional 1,460,205 shares during the last quarter. State Street Corp raised its holdings in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock valued at $26,625,000 after buying an additional 762,953 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Remove Ads

Roivant Sciences Trading Down 1.6 %

NASDAQ ROIV traded down $0.18 during trading on Tuesday, hitting $10.68. The company had a trading volume of 1,501,245 shares, compared to its average volume of 5,489,541. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market cap of $7.62 billion, a price-to-earnings ratio of -71.16 and a beta of 1.26. The company's fifty day moving average is $10.80 and its 200-day moving average is $11.49.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ROIV shares. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $18.08.

Insider Buying and Selling

In other news, COO Eric Venker sold 176,900 shares of the firm's stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the sale, the chief operating officer now owns 668,680 shares of the company's stock, valued at $7,903,797.60. This trade represents a 20.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CIO Mayukh Sukhatme sold 412,584 shares of the firm's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. The trade was a 2.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,388,170 shares of company stock worth $27,612,299 in the last three months. 7.90% of the stock is owned by corporate insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.